informaworld logo
HOME . ABOUT US . CONTACT US 		HELP . PUBLISH WITH US . LIBRARIANS 
ebooks logo journals logo reference works logo abstract databases logo
bullet  SIGN IN Register | Why Register? | Got a Voucher? alerts   marked lists   shopping cart 
Session timed out - new session started. You may need to sign in again. [ hide message ]
Advert: Informa Healthcare - http://www.informahealthcare.com

informaworld

HOME   |   SEARCH   |   BROWSE
    Issues List       Latest Issue       Forthcoming Articles       Volume 5 Supplement 1       Aims & Scope       Editorial Board       Instructions for Authors       Subscribe      
<< earliestearliest   < prevprev   Issue listissues   next >next   latest >>latest
Publisher Logo Publication Cover
Search within this journal

Amyotrophic Lateral Sclerosis, Volume 5 Supplement 1 2004

Amyotrophic Lateral Sclerosis is moving!
The official publication of the World Federation of Neurology Research Group on Motor Neuron Disease
2008 Impact Factor: 1.815 (ISI Web of Knowledge, 2008 Journal Citation Reports)
ISSN: 1471-180X (electronic) 1748-2968 (paper)
Publication Frequency: 6 issues per year
Subject: Neurology;
Previously published as: Amyotrophic Lateral Sclerosis and other Neuron Disorders (1466-0822, 1471-180X) until 2006
Viewing the Journal: Select the initial letter of your research topic from the list below, or enter your search term on the left.
Sort by: Title | Page | Author
< Previous • 1 • 2 • Next >
View new articles ahead of the print edition
select-down Click for help
Foreword
Foreword
Gerald D. Fischbach
Page 5
Abstract | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Introduction
Preface
Hiroshi Mitsumoto; Serge Przedborski
Pages 6 – 7
Abstract | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Randomized control trials in ALS: lessons learned
Hiroshi Mitsumoto;  Paul Gordon;  Petra Kaufmann;  Clifton Gooch;  Serge Przedborski; Lewis P. Rowland
Pages 8 – 13
Abstract | References | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Bench to clinic
Molecular targets for neuroprotection
Serge Przedborski
Pages 14 – 18
Abstract | References | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
High throughput drug screening
Jill Heemskerk
Pages 19 – 21
Abstract | References | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Preclinical studies: how much can we rely on?
Jeffrey D. Rothstein
Pages 22 – 25
Abstract | References | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Lessons learned from other neurological diseases
Parkinson's disease
Stanley Fahn
Pages 26 – 30
Abstract | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Stroke
Jay P. Mohr
Pages 31 – 33
Abstract | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Neuro-Oncology
S Clifford Schold Jr
Pages 34 – 35
Abstract | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Issues in Clinical Trials
Regulatory issues in ALS clinical trials
Wilson W. Bryan
Pages 36 – 41
Abstract | References | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Randomized controlled trials
John Marler
Page 42
Abstract | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Statistical issues
Bruce Levin
Pages 43 – 45
Abstract | References | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Data Safety Monitoring Board (DSMB)
KMA Welch
Pages 46 – 47
Abstract | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Missing data
John LP Thompson; Gilberto Levy
Pages 48 – 51
Abstract | References | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Study design
ALS trial design: expectation and reality
Robert G. Miller; Dan H. Moore
Pages 52 – 54
Abstract | References | Full Text PDF | Request Permissions
Cited By | Related Articles 		 buy now buy now
An efficient multi-stage, single-arm Phase II futility design for ALS
Yuko Y. Palesch; Barbara C. Tilley
Pages 55 – 56
Abstract | References | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Improving efficiency of ALS clinical trials using lead-in designs
Dan H. Moore II; Robert G. Miller
Pages 57 – 60
Abstract | References | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Design using historical controls
Albert Yen;  Ericka Simpson;  Lanny Haverkamp; Stanley Appel
Pages 61 – 63
Abstract | References | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Natural history is a moving target
Baseline disease characteristics
P. N. Leigh
Pages 64 – 67
Abstract | References | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Disease-modifying drug therapies
Benjamin R. Brooks; Mohammed Sanjak
Pages 68 – 75
Abstract | References | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Disease-modifying interventions
Edward Kasarskis
Pages 76 – 78
Abstract | References | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Endpoints
Survival
J. Cedarbaum
Pages 79 – 83
Abstract | References | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Maximum voluntary isometric contraction (MVIC)
Merit Cudkowicz;  Hui Zhang;  Muhammad Qureshi; David Schoenfeld
Pages 84 – 85
Abstract | References | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
Assessment of strength measurements
Eric J. Sorensen
Pages 86 – 89
Abstract | References | Full Text PDF | Request Permissions
Related Articles 		 buy now buy now
select-up

Privacy Policy | Terms & Conditions | Accessibility | RSS
FAQs in: English . Français . Español . 中文（简体和繁體）
© 2009 Informa plc